Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H27N5O4.2ClH |
| Molecular Weight | 498.403 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OCCNCCNC1=CC=C2N(CCNCCO)N=C3C2=C1C(=O)C4=C3C=CC=C4O
InChI
InChIKey=XDMHALQMTPSGEA-UHFFFAOYSA-N
InChI=1S/C22H27N5O4.2ClH/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29;;/h1-5,23-25,28-30H,6-13H2;2*1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C22H27N5O4 |
| Molecular Weight | 425.4809 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Losoxantrone is an anthrapyrazole that induces both single and double strand breaks in DNA and is a potent inhibitor of DNA synthesis. The drug is in clinical trials for the treatment of breast cancer and of prostate cancer that is refractory to androgen ablation. Acute toxicity is negligible. Losoxantrone may be less cardiotoxic than doxorubicin. Up to 40% of patients encounter alopecia. 3% of patients develop congestive heart failure. Losoxantrone had been in phase II clinical trial for the treatment of breast and prostate cancer. However, this development was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Monotherapy of metastatic breast cancer: a review of newer agents. | 1999 |
|
| The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane. | 1999 Nov-Dec |
|
| A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer. | 2000 Apr |
|
| A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. | 2001 |
|
| Elimination pathways of [14C]losoxantrone in four cancer patients. | 2001 Feb |
|
| DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. | 2001 Jan |
|
| Separation methods for anthraquinone related anti-cancer drugs. | 2001 Nov 25 |
|
| The oxidative biotransformation of losoxantrone (CI-941). | 2002 Apr |
|
| Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. | 2002 Feb 12 |
|
| A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. | 2006 Jul-Aug |
|
| Structure-activity studies with cytotoxic anthrapyrazoles. | 2006 Jun |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:01:49 GMT 2023
by
admin
on
Sat Dec 16 07:01:49 GMT 2023
|
| Record UNII |
JWB98HG9FS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
88303-61-1
Created by
admin on Sat Dec 16 07:01:49 GMT 2023 , Edited by admin on Sat Dec 16 07:01:49 GMT 2023
|
PRIMARY | |||
|
73349
Created by
admin on Sat Dec 16 07:01:49 GMT 2023 , Edited by admin on Sat Dec 16 07:01:49 GMT 2023
|
PRIMARY | |||
|
DTXSID70236950
Created by
admin on Sat Dec 16 07:01:49 GMT 2023 , Edited by admin on Sat Dec 16 07:01:49 GMT 2023
|
PRIMARY | |||
|
JWB98HG9FS
Created by
admin on Sat Dec 16 07:01:49 GMT 2023 , Edited by admin on Sat Dec 16 07:01:49 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
